90y-dota-tyr3-octreotide
PeptideexperimentalADC
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2004 (NCT04029428)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- SomatostatinBINDING AGENT
SST binding agent
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- 90y-dota-tyr3-octreotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04296149 | Phase 2 | Feb 16, 2017 | University of Milan |
| NCT02441088 | Phase 2 | May 1, 2015 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Iowa |
| NCT04029428 | Phase 2 | Nov 2, 2004 | Association of Patients and Supporters of Neuroendocrine Tumors, Warsaw, Poland, University of Warmia and Mazury |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Association of Patients and Supporters of Neuroendocrine Tumors, Warsaw, Poland | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2015 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Warmia and Mazury | Academic/Hospital | 1 | 1 | 1 | 2004 |
6 organizations
Page 1 / 1